Genomic ctDNA-Informed De-escalation And Neoadjuvant Chemotherapy Omission in Cystectomy

November 12, 2026 updated by: Case Comprehensive Cancer Center

GUIDANCE-MIBC: Genomic ctDNA-Informed De-escalation And Neoadjuvant Chemotherapy Omission in Cystectomy

This study is for participants who have recently been diagnosed with muscle-invasive bladder cancer (MIBC) who are eligible for the surgical removal of the entire bladder, and have undergone ctDNA testing with a negative result. The purpose of this study is to investigate the outcomes for ctDNA negative MIBC participants who do not receive neoadjuvant chemotherapy before undergoing bladder removal.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

Muscle-invasive bladder cancer is an aggressive form of cancer with a high chance of metastasis at the time of diagnosis. The standard of care treatment for MIBC is neoadjuvant chemotherapy (NAC), followed by radical cystectomy or removal of the entire bladder, and then pelvic lymph node dissection. While NAC improves the overall survival at 5 years, it is associated with significant toxicities and there are many patient who do not benefit from it. Because of this, there is a need for predictive biomarkers to identify participants who can directly go into surgery without undergoing NAC. Recent studies have shown circulating tumor DNA (ctDNA) to be highly sensitive and specific predictive biomarker, and ctDNA negative participants have excellent outcomes and that skipping NAC is not harmful for these participants. The aim of this study is find out the safety and efficacy of omitting NAC in participants with MIBC who are ctDNA negative before their planned radical cystectomy. By using personalized ctDNA biomarkers, this will help spare patients the toxicity and delay unnecessary chemotherapy while still maintaining excellent outcomes.

Study Type

Interventional

Enrollment (Estimated)

150

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Laura Bukavina, MD, MPH, MSc
  • Phone Number: (216) 444-6043
  • Email: bukavil2@ccf.org

Study Contact Backup

Study Locations

    • Ohio
      • Cleveland, Ohio, United States, 44106
        • Cleveland Clinic Foundation
        • Contact:
          • Laura Bukavina, MD, MPH, MSc
          • Phone Number: (216) 444-6043
          • Email: bukavil2@ccf.org
        • Principal Investigator:
          • Laura Bukavina, MD, MPH, MSc

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Histologically confirmed muscle-invasive urothelial carcinoma of the bladder (cT2- T4aN0M0).
  • Planned for radical cystectomy with curative intent.
  • Negative for ctDNA using a validated, tumor-informed assay (Natera Signatera) from a blood sample collected prior to any systemic therapy. Must have 2 negative tests within the screening window.
  • Age ≥ 18 years.
  • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2.
  • Adequate organ function as defined by standard laboratory criteria.
  • Ability to understand and provide written informed consent.

Exclusion Criteria:

  • Evidence of clinical node-positive or metastatic disease (cN+ or cM1) on baseline imaging.
  • Prior systemic therapy (chemotherapy or immunotherapy) for urothelial carcinoma within the past 12 months.
  • Positive ctDNA status at baseline (defined as a positive result on either of the two pre-operative Natera Signatera tests).
  • Variant histology comprising >50% of the tumor volume (e.g., small cell, sarcomatoid, plasmacytoid).
  • Uncontrolled concurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, or psychiatric illness that would limit compliance with study requirements.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: ctDNA-negative MIBC

There will be a pilot lead-in phase for the first 30 participants who are eligible due to the risks associated. Participants who are newly diagnosed with MIBC who are candidates for radical cystectomy will undergo baseline ctDNA test. Participants who are confirmed to be ctDNA negative will be enrolled in the study and will proceed directly to radical cystectomy without neoadjuvant chemotherapy (NAC). After surgery, participants will undergo standard of care assessments.

Newly diagnosed MIBC participants who are candidates for radical cystectomy will first undergo baseline ctDNA testing to see if they are ctDNA negative. If the participant is confirmed ctDNA negative, they will be enrolled in the study and undergo radical cystectomy without neoadjuvant chemotherapy.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Recurrence free survival (RFS)
Time Frame: 2 years

RFS is defined as the time from the date of cystectomy in ctDNA-negative MIBC participants to the date of first documented radiological recurrence per RECIST v1.1 or death, whichever occurs first.

2 years

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Overall survival (OS)
Time Frame: at 2 years

Overall survival is defined as the duration of time from the start of treatment to time of death from any cause.

at 2 years
Overall survival
Time Frame: at 5 years

Overall survival is defined as the duration of time from the start of treatment to time of death from any cause.

at 5 years
Rate of pathological complete response (pCR)
Time Frame: at day 0

To assess the rate of pathological complete response and pathological tumor characteristics at the time cystectomy.

at day 0
Rates of surgical morbidity
Time Frame: up to 4 weeks

To evaluate surgical morbidity in participants undergoing only cystectomy compared to participants receiving neoadjuvant therapy.

up to 4 weeks
Rates of complications
Time Frame: up to 4 weeks

To evaluate complications in participants undergoing only cystectomy compared to participants receiving neoadjuvant therapy.

up to 4 weeks
Positive predictive value
Time Frame: days -42 to 0

To evaluate the positive predictive value of baseline ctDNA status for pathological lymph node involvement

days -42 to 0
Negative predictive value
Time Frame: days -42 to 0

To evaluate the negative predictive value of baseline ctDNA status for pathological lymph node involvement

days -42 to 0

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Collaborators

Investigators

  • Principal Investigator: Laura Bukavina, MD, MPH, MSc, The Cleveland Clinic

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

January 1, 2027

Primary Completion (Estimated)

January 1, 2029

Study Completion (Estimated)

December 1, 2032

Study Registration Dates

First Submitted

November 12, 2026

First Submitted That Met QC Criteria

November 12, 2026

First Posted (Actual)

November 18, 2026

Study Record Updates

Last Update Posted (Actual)

November 18, 2026

Last Update Submitted That Met QC Criteria

November 12, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • CASE9826

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

There is not currently an intention or plan to share IPD

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.